Amgen’s Trebananib Meets First Phase III Goal In Ovarian Cancer

Amgen’s trebananib (AMG 386) meets progression-free survival endpoint in Phase III TRINOVA-1 recurrent ovarian cancer study, but higher dropout rate than expected needs explanation. Company also moves IL-17 inhibitor brodalumab into Phase III for psoriatic arthritis.